Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now?
Summary of data in the metastatic setting.
|Author (year)||Line of treatment|
Type of trial
|Drug(s)||Number of patients evaluable for end points||Results|
|Yoshimoto et al. ||1st-2nd line|
|CAPE 828 mg/m2 twice daily + CTX 33 mg/m2 twice daily, dd 1 → 14, every 21 days||9||ORR 44.4%|
Median PFS 10.7 months
|Wang et al. ||2nd line or further|
|CTX 50 mg daily (after CTX 3 g/m2 for the preparation of CD34+ and CTX 3 g/m2, thiotepa 150 mg/m2, and CBDCA AUC = 6, every 28 dd for 2 courses)||23||NA|
|Kummar et al. ||2nd line or further|
|CTX 50 mg/day|
CTX 50 mg/day + Veliparib 60 mg once daily throughout a 21-day cycle
|39||ORR 5.6% versus 9.5%|
|ORR = overall response rate; CBR = clinical benefit rate; PFS = progression-free survival; CBDCA = carboplatin.|